Pyxis Oncology, Inc. (NASDAQ:PYXS) Short Interest Update

Pyxis Oncology, Inc. (NASDAQ:PYXS) was the recipient of a large drop in short interest during the month of April. As of April 15th, there was short interest totaling 2,269,065 shares, a drop of 14.7% from the March 31st total of 2,660,931 shares. Based on an average trading volume of 402,636 shares, the short-interest ratio is presently 5.6 days. Currently, 4.0% of the company’s shares are short sold.

Institutional Trading of Pyxis Oncology

Several hedge funds have recently modified their holdings of PYXS. Laurion Capital Management LP boosted its stake in shares of Pyxis Oncology by 32.3% in the fourth quarter. Laurion Capital Management LP now owns 4,796,479 shares of the company’s stock valued at $5,516,000 after buying an additional 1,170,505 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Pyxis Oncology by 0.7% during the 3rd quarter. Vanguard Group Inc. now owns 2,163,962 shares of the company’s stock worth $4,804,000 after purchasing an additional 14,566 shares during the period. 683 Capital Management LLC lifted its stake in shares of Pyxis Oncology by 69.9% in the fourth quarter. 683 Capital Management LLC now owns 891,910 shares of the company’s stock valued at $1,026,000 after purchasing an additional 366,910 shares during the period. Jane Street Group LLC grew its position in Pyxis Oncology by 158.8% during the fourth quarter. Jane Street Group LLC now owns 786,010 shares of the company’s stock worth $904,000 after buying an additional 482,310 shares during the period. Finally, Renaissance Technologies LLC lifted its position in shares of Pyxis Oncology by 26.4% during the 4th quarter. Renaissance Technologies LLC now owns 728,380 shares of the company’s stock valued at $838,000 after acquiring an additional 152,044 shares during the period. 39.07% of the stock is owned by institutional investors and hedge funds.

Pyxis Oncology Trading Up 1.2%

PYXS opened at $1.72 on Friday. The company has a market capitalization of $108.07 million, a price-to-earnings ratio of -1.33 and a beta of 1.43. The business’s fifty day simple moving average is $1.55 and its 200-day simple moving average is $2.38. Pyxis Oncology has a 12-month low of $0.97 and a 12-month high of $5.55.

Pyxis Oncology (NASDAQ:PYXS) last issued its earnings results on Monday, March 23rd. The company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.06. The firm had revenue of $11.04 million during the quarter, compared to analysts’ expectations of $0.13 million. On average, equities research analysts predict that Pyxis Oncology will post -1.24 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the company. Stifel Nicolaus reduced their target price on Pyxis Oncology from $9.00 to $8.00 and set a “buy” rating on the stock in a research note on Tuesday, March 24th. HC Wainwright restated a “buy” rating and issued a $7.00 price target on shares of Pyxis Oncology in a report on Tuesday, March 24th. Wall Street Zen raised shares of Pyxis Oncology from a “sell” rating to a “hold” rating in a research note on Monday, April 13th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Pyxis Oncology in a report on Thursday, January 22nd. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Pyxis Oncology has an average rating of “Moderate Buy” and a consensus price target of $7.00.

About Pyxis Oncology

Pyxis Oncology (NASDAQ: PYXS) is a clinical?stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody?drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off?target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early?stage ADC candidates directed against a variety of solid tumor antigens.